THE 7 MISTAKES NEW USERS MAKE IN THEIR FIRST CYCLE

The most common technical error. Peptides arrive as lyophilized (freeze-dried) powder measured in milligrams or micrograms. You reconstitute with bacteriostatic water, then draw from the resulting solution. If your math is wrong, you're either dramatically underdosing or overdosing — and either way, you have no idea.

The error happens in the unit conversion: milligrams to micrograms, and then from solution concentration to syringe volume. A 5mg vial reconstituted with 2mL of bacteriostatic water gives a 2.5mg/mL solution. To draw 250mcg (0.25mg), you need 0.1mL — the 10-unit mark on a standard 100-unit insulin syringe. Most new users get this wrong at least once. Write the math before you draw. Use the calculator on this site. Recheck it every time.

The appeal is understandable: more compounds, more effects. The reality is that stacking multiple peptides on a first cycle makes it impossible to identify what's working, what's causing side effects, or why nothing is happening. If you're running BPC-157, TB-500, Ipamorelin, and CJC-1295 simultaneously and feel nothing, you have no idea which compound is the problem.

Start with a single compound that matches your primary goal. Run it for 8–12 weeks at a consistent dose. Track your response. Then add compounds in subsequent cycles once you have a baseline understanding of how your body responds to each one individually. Stacking is for users who already know how they respond to the individual compounds.

If you didn't measure anything before you started, you have no way to know if anything changed. This sounds obvious; almost nobody does it. For GH secretagogues, get IGF-1 measured at baseline. For any protocol affecting body composition, measure weight, body fat percentage, and ideally girth measurements before day 1. For anything affecting recovery or sleep, keep a daily log.

Bloodwork before starting any peptide protocol isn't optional — it's the only way to detect subclinical issues that might affect your response, and it's the only way to see whether the compound is doing what it's supposed to do. For GH peptides, IGF-1 is the key marker. Run it at baseline and at 8 weeks.

Mistake 4 — Inconsistent injection site rotation: Injecting repeatedly into the same subcutaneous site causes lipohypertrophy — fatty lumps under the skin that impair absorption and produce inconsistent dosing. Rotate sites systematically: abdomen quadrants, thighs, and flanks, moving at least 1–2cm between injections. Published data on insulin users shows that lipohypertrophy is associated with significantly higher insulin dose requirements — the same principle applies to peptides.

Mistake 5 — Cycling too short: Most peptides require time for effects to accumulate. GH secretagogues typically show meaningful body composition changes only after 8–12 weeks of consistent use. Running a 4-week cycle and measuring at week 5 is the most common reason users incorrectly conclude a compound didn't work.

Mistake 6 — Choosing a source based on price: The research peptide market has no regulatory equivalent to pharmaceutical manufacturing quality controls. Price is not inversely correlated with quality. A cheap source that passes its own in-house HPLC test may still be delivering 60% of the labeled concentration, or product contaminated during synthesis. Third-party mass spectrometry testing is the minimum meaningful quality signal.

Mistake 7 — No tracking protocol: Keep a log. Date, compound, dose, injection site, any side effects, energy levels, sleep quality, training performance, and recovery. Subjective data is still data. The users who get the most out of peptide protocols are those who treat their own response as the research subject it is — with systematic observation, not guesswork.